Lupin Limited · NSE:LUPIN
Lupin — Q2 FY2019 Earnings Presentation
16 slides from Lupin's earnings presentation, Oct 31, 2018
Slide 1: Lupin Limited Investor Presentation Q2 FY 2019
LUPIN LIMITED Investor presentation Q2 FY 2019 Oct 31, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 3: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Dr. Desh Bandhu Gupta inducted into the ‘Hall of Fame’, CNBC-TV18 - India Business Leader Awards 2018 • Vinita Gupta - Vogue and IBM Business Woman of the Year - 2018 • Innovator Award from BioNJ, New Jersey - 2018 • Walmart Supplier of the Year Award - 2018 • India Ph
Slide 4: Q2FY19 Snapshot
Q2FY19 Snapshot Sales (INR mn, YoY growth) Important developments India, North America, Regulatory 12,032 , 4% 12,487 , (8%) Mr. Nilesh.D.Gupta Managing Director • Warning Letter resolution on track Lupin Limited Total • Nagpur, Tarapur and Pithampur (Unit 3) 38,909, 0.4% facilities underwent USFDA
Slide 5: Tracking FY19 priorities: H1FY19 scorecard
Tracking FY19 priorities: H1FY19 scorecard Generics Gaining market share in the US - Average market share for Lupin products inched up to 32.8% in Q2 FY191 (vs 31.3% in Q4 FY18) Maintaining superior growth momentum in India - Expanded anti diabetes partnership with Boehringer Ingelheim and Eli L
Slide 6: Our Strategic Vision: Well-Diversified Pharma business
Our Strategic Vision: Well-Diversified Pharma business Strong Complex Specialty Focus Foundation Generics Focus Amongst the Top 10 Investing heavily in Committed to building a generic companies in the developing high barrier strong specialty business World products Sustain and Grow Evolve portfolio
Slide 7: Q2FY19 Financial Results Review
Q2FY19 Financial Results Review
Slide 8: P&L Highlights – Q2 FY19
P&L Highlights – Q2 FY19 QoQ YoY Amount in INR mn Q2 FY19 % of sales Q1 FY19 % of sales Q2 FY18 % of sales growth growth Net sales 38,909 100.0% 37,746 100.0% 3.1% 38,742 100.0% 0.4% Other operating income 601 814 778 Total revenue 39,510 38,560 2.5% 39,520 0.0% Gross profit 24,981 64.2% 23,304 61.7
Slide 9: P&L Highlights – H1 FY19
P&L Highlights – H1 FY19 Amount in INR mn 1H FY19 % of sales 1H FY18 % of sales YoY growth Net sales 76,655 100.0% 76,810 100.0% (0.2%) Other operating income 1,415 1,404 Total revenue 78,070 78,214 (0.2%) Gross profit 48,285 63.0% 51,618 67.2% (6.5%) (excl. other operating income) EBITDA 14,915 19.
Slide 10: North America
Q2FY19 North America 32% YoY QoQ 8.3% 5.3% US revenues stabilizing Lupin consolidating its position in US1 US quarterly sales ($ mn) 120 #4 #3 7 213 224 100 111 6 204 #4 109 #5 5 168 171 80 #6 79 83 4 60 64 3 57 40 51 44 45 2 20 28 1 0 0 2014-15 2015-16 2016-17 2017-18 MAT Sep-18 Q2 FY18 Q3 FY18 Q4
Slide 11: India
Q2FY19 India 31% YoY QoQ 3.8% 0.9% Modest YoY growth on high base Healthy growth seen across therapy groups India quarterly Sales (INR bn) Q2 FY19 Growth1 Lupin Rank1 MAT MAT 11.6 11.9 12.0 Therapy Market Lupin 10.7 Sep-14 Sep-18 9.6 Acute 12 11 14 12 Chronic 15 22 5 4 Cardiac 14 21 2 3 Anti-diabeti
Slide 12: APAC
Q2FY19 APAC 16% YoY 2.5% QoQ 2.0% APAC sales evolution (INR bn) 1.2 1.6 Performance highlights 1.3 1.1 1.1 Japan 5.1 5.6 5.1 5.0 5.1 • Biennial pricing cuts impacted Japan pharma market growth Q2 FY18 Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 Philippines Japan APAC (Ex Japan) • Ranked 5th branded Gx player2 •
Slide 13: Other markets: Developed and Emerging
Other markets Developed • Germany: EUR 7.3 mn sales in Q2FY19 EU5 • ARV’s, Women´s Health and CNS are the key focus therapeutic segments • NaMusclaTM (Mexiletine) received positive CHMP opinion • 4th largest generics player & #3 generic company by prescriptions South • Q2FY19 revenues grew 5% YoY to
Slide 14: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence OPERATIONS 100 25 9 Countries where Countries with Countries with RESEARCH products are sold marketing offices subsidiaries 18 9 Manufacturing Sites R&D Sites • 8 USFDA approved sites • 405 US ANDAs; 247 approved • 12 USFDA in
Slide 15: Continued investments in growth initiatives
Continued investments in growth initiatives Invested INR 3.8 bn or 9.7% of sales on R&D in Q2FY19 at 9 R&D sites globally Optimizing R&D spend US Pipeline R&D Spend (INR Bn) % of sales 5,000 12.2% 12.2% 14.0% 405 cumulative filings 4,500 10.1% 12.0% 4,000 9.9% 9.7% 3,500 10.0% 3,000 8.0% 2,500 158 p
Slide 16: Thank You!
SC in LUPIN THANK YOU! :